Research and Development-- CHI supports and conducts research to better understand, treat, manage, and hopefully cure HI. CHI shares the patient perspective with researchers and members of the biopharmaceutical industry to accelerate the development of patient-centered treatments, and provides patient-experience consulting to biotechnology companies and researchers developing investigational treat… Read more
Research and Development-- CHI supports and conducts research to better understand, treat, manage, and hopefully cure HI. CHI shares the patient perspective with researchers and members of the biopharmaceutical industry to accelerate the development of patient-centered treatments, and provides patient-experience consulting to biotechnology companies and researchers developing investigational treatments for HI.CHI is a part of the Million Dollar Bike Ride grant program with the University of Pennsylvania's Center for Orphan Diseases; a pilot research grant is offered each year for an innovative, preclinical or clinical study with the potential to lead to a better HI treatment, a cure for HI, or improvement in the quality of life for those affected by HI. In 2025, CHI was able to award one pilot research grant through this program, supported in part by the annual Million Dollar Bike Ride fundraising event held in Philadelphia, PA. The period for this awarded grant begins on October 1,2026.CHI conducts the HI Global Registry (HIGR) research project, an online platform for the HI patient community to share their experiences of living with HI and their glucose monitoring values. With the patient families' permission, MaxHIGR provides complementary data from the physician's perspective. By participating in the HI Global Registry, the patient community helps themselves and researchers better understand HI to advance better treatments, a potential cure, and more timely and accurate diagnoses. A HIGR report is published each year by CHI staff, and scholars and researchers may request deidentified data for their research projects. In 2025, CHI launched a partnership with Dexcom to improve access to continuous glucose monitors (CGM) for members of the HI community in the United States.In 2025, CHI also continued or launched several additional research initiatives, including the HI Global Registry, the HI/HA Natural History Study, and a pancreatectomy research study, along with ongoing research resources maintained on CHI's website. In 2025, CHI research was also presented via posters at the following meetings: the Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, Denmark; the PES Annual Meeting in National Harbor, MD; the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL; the 2025 NORD Breakthrough Summit in Washington, DC; the Diabetes Technology Meeting hosted by the Diabetes Technology Society in Burlingame, CA; The Global Pediatric Endocrine and Diabetes Annual Meeting 2025 (virtual);and Hot Topics in Neonatology, hosted by Nemours Children's Health, in Washington, DC. CHI staff also attended and presented at the Chan Zuckerberg Initiative (CZI) Science in Society: Rare As One Network Meeting (Nevada), and the CZI Ciliopathies in Focus Workshop, Redwood City, CA.In 2025, CHI continued to lead the Collaborative Research Network (CRN), a project of CHI dedicated to the development of faster and more accurate diagnoses, new evidence-based treatments and cures, standardized clinical guidelines, and increased and improved access to treatment, medication, devices, and supplies. This ambitious project includes working groups focused on different aspects of a prioritized research agenda (PRA) developed by the CRN's members, which include 60 leading researchers, clinicians, and patient advocates from 17 countries. In 2025, the CRN held virtual meetings throughout the year as well as an in-person convening in Lisbon, Portugal (February 28March 2), and advanced small-group projects on Universal Newborn Screening, Continuous Glucose Monitoring for HI, and advocacy focused on access and on awareness reflecting the PRA's top priorities of Newborn Screening, Glucose as a Vital Sign, Care Guidelines, Natural History, and Continuous Glucose Monitoring. Since the CRN's launch in 2020, its members have published a total of 198 articles on congenital hyperinsulinism covering genetics, treatment, disease management, monitoring and technology, screening and diagnostics, clinical guidelines, education, patient experience, quality of life, policy, and access to care.In 2025, CHI staff and CHI Collaborative Research Network (CRN) members co-authored or contributed to several peer-reviewed publications, including:EndoCompass project: research roadmap for diabetes, obesity, and metabolism, adapted the results of the CRN's congenital hyperinsulinism prioritized research agenda for adoption by the European Society for Endocrinology and the European Society for Paediatric Endocrinology through the EndoCompass Research Roadmap.Global Disparities in Congenital Hyperinsulinism Care, highlighting limitations in care access worldwide and calling for collaborative research to promote equitable care;Real-world experience with the use of diazoxide among people living with congenital hyperinsulinism and their caregivers, drawing on HI Global Registry (HIGR) data and qualitative interviews to examine diazoxide use, side effects, and daily quality-of-life impact;Developing a congenital hyperinsulinism prioritized research agenda: a patient-driven international collaborative research network, published in Frontiers in Endocrinology, sharing the CRN's roadmap of research priorities to advance diagnosis, treatment, and cures for HI.Additionally, CHI staff and CHI Collaborative Research Network (CRN) members co-authored the following publication:Neonatal hypoglycaemia: consider hyperinsulinism, an overview for midwives, neonatal nurses, and other birthing professionals on the importance of severe hypoglycemia detection; andCHI continues to support the Open Hyperinsulinism Genes Program in partnership with the University of Exeter in the UK. This program is the first point-of-need international genetic testing service for HI and is also accelerating scientific knowledge through the creation of a self-sustaining research gene discovery pipeline. As of December 31, 2025, 1,176 samples from individuals affected by congenital hyperinsulinism and 871 samples from family members, from 65 countries on 5 continents, have been tested through this program.In 2025, CHI continued to support the CHI Centers of Excellence Designation. Currently, eight centers around the world have been granted the designation and are recognized as multi-disciplinary clinical and research centers in the field of congenital hyperinsulinism. The goals of this program are to make it easier for patient families to access care at leading hospitals, encourage patient-focused standards at the leading hospitals, foster a pipeline of expert clinicians and researchers, and encourage collaboration among researchers, clinicians, and patient leaders and advocates.In 2025, CHI continued its work as part of the international, 11-member LightCure Consortium, a project made possible by a grant from the European Union research arm Horizon Europe encompassing CHI's work to strengthen patient engagement and raise worldwide awareness of HI and its myriad challenges. The Consortium held an in-person meeting in Lisbon, Portugal, and in 2025 CHI released its documentary short film, Turn Hours into a Lifetime, which follows three hyperinsulinism families from around the world and highlights the importance of detecting and treating severe hypoglycemia early to prevent brain damage and death.